Posted by Michael Wonder on 12 Nov 2017
NHS England, Roche come to agreement on Perjeta
10 November 2017 - NHS England and Roche have agreed a confidential commercial agreement on the price of Perjeta for certain patients with breast cancer.
The move now allows NICE to carry out the final stage of its appraisal for the drug “and opens the way for continued access to this important treatment for breast cancer,” NHS England said.
Perjeta (pertuzumab), which is licensed to treat HER2-positive breast cancer which has spread to other parts of the body, cannot be surgically removed and has stopped responding to other treatments, will remain available via the Cancer Drugs Fund while NICE independent appraisal committee reviews the new arrangement before issuing guidance.
The drug has been available via the Cancer Drugs Fund since 2013, benefiting around 1,300 patients per year.
